Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Blood (2023) 142 (Supplement 1): 5024.

https://doi.org/10.1182/blood-2023-180691

Published: 2023

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Blood (2023) 142 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2023-189676

Published: 2023

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Mireya Morote-Faubel, Maria Guaita-Céspedes, Beatriz Fernández-Blanco, Cristina Martínez-Valiente, Cristian García-Ruiz, Marta Santiago, Alvaro Diaz-Gonzalez, Alejandra Sanjuan-Pla, Mariam Ibáñez, Eva Barragan, Esperanza Such, Mireya Morote Faubel, Pau Montesinos, Javier De La Rubia, Alessandro Liquori, Jose Cervera

Blood (2023) 142 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2023-177571

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Blood (2022) 140 (Supplement 1): 9100–9102.

https://doi.org/10.1182/blood-2022-163016

Published: 2022

Journal Articles

Prognostic Impact of NPM1 and FLT3 -ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Blood (2022) 140 (Supplement 1): 6077–6079.

https://doi.org/10.1182/blood-2022-167365

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Blood (2022) 140 (Supplement 1): 3422–3424.

https://doi.org/10.1182/blood-2022-166639

Published: 2022

Journal Articles

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Blood (2021) 138 (Supplement 1): 1302.

https://doi.org/10.1182/blood-2021-152353

Published: 2021

Journal Articles

Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm) and Their Clinical Impact

María Poza, MD, Rafael Colmenares, MD, Alba González, Noemi Alvarez, Gonzalo Carreño Gomez-Tarragona, MD, Esther Onecha, PhD, María Teresa Cedena, MD, Pilar Martínez, MD, Juan Manuel de la Rosa, Inmaculada Rapado, PhD, Eva Barragán, PhD, Pau Montesinos, MD PhD, Rafael Llobet, Miguel Sanz, MD PhD, Joaquin Martinez-Lopez, MD PhD, Rosa Ayala, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141534

Published: 2020

Journal Articles

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Rosa Ayala, MD PhD, Pau Montesinos, MD PhD, Eva Barragán, PhD, Joaquin Martinez-Lopez, MD, Miguel A. Sanz, Yanira Ruiz-Heredia, Santiago Barrio, Juan Manuel de la Rosa, Inmaculada Rapado, Pilar Martinez, MD, Rafael Colmenares, Maria Pozas, Xabier Gutierrez, María Luz Morales, Noemí Álvarez Sánchez-Redondo

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137467

Published: 2020

Journal Articles

Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients

Blood (2019) 134 (Supplement_1): 5368.

https://doi.org/10.1182/blood-2019-127069

Published: 2019

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia (AML)

Christian Thiede, MD, Thomas W Prior, MD, Serena Lavorgna, PhD, Jürgen Krauter, MD, Eva Barragán, Josep Nomdedeu, MD PhD, Joop H. Jansen, Andrew H Wei, MBBS, PhD, Weiqiang Zhao, MD PhD, Xiaohong Li, Celine Pallaud, PhD, Eva Tiecke, PhD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard M. Stone, MD, Konstanze Döhner, MD

Blood (2018) 132 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2018-99-112127

Published: 2018

Journal Articles

Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms

Blood (2017) 130 (Supplement 1): 3956.

https://doi.org/10.1182/blood.V130.Suppl_1.3956.3956

Published: 2017

Journal Articles

Rapid Screening of Targetable Kinase Gene Fusions in Acute Lymphoblastic Leukemia

Esperanza Such, Gayane Avetisyan, Iván Martín, Inés Gómez-Seguí, PhD, Francisca García, Eva Villamón, PhD, Alessandro Liquori, PhD, Francisco Mares, MD, Marta Llop, Paula Amat, MDPhD, Mariam Ibañez, Eva Barragán, Mar Tormo, MD PhD, Guillermo Sanz, MD, Carlos Solano, MD PhD, José Cervera, MD PhD, Blanca Navarro, Miguel A. Sanz, MD

Blood (2017) 130 (Supplement 1): 1436.

https://doi.org/10.1182/blood.V130.Suppl_1.1436.1436

Published: 2017

Journal Articles

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Blood (2016) 128 (22): 598.

https://doi.org/10.1182/blood.V128.22.598.598

Published: 2016

Journal Articles

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Esther Onecha, Joan Ballesteros, Jose L Rojas, Jose M Sanchez, Eva Barragan, PhD, Inmaculada Rapado, PhD, Santiago Barrio, David Martinez, MD PhD, Pau Montesinos, MD, Pilar Herrera, MD PhD, Carmen Burgaleta, MD, Joaquin Martinez-López, MDPhD, Rosa M. Ayala, MD PhD

Blood (2015) 126 (23): 1376.

https://doi.org/10.1182/blood.V126.23.1376.1376

Published: 2015

NARROW

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Prognostic Impact of NPM1 and FLT3 -ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm) and Their Clinical Impact

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia (AML)

Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms

Rapid Screening of Targetable Kinase Gene Fusions in Acute Lymphoblastic Leukemia

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only